Apnimed ^{Priced, Nasdaq: APMD}

We are a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Our sole clinical product candidate, Oxnimbi, is an investigational, fixed-dose anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective NRI for the treatment of OSA. Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep. Based on results from two registrational trials, we submitted a NDA for Oxnimbi to the FDA in April 2026. The registrational trials were Phase 3 randomized, double-blind, placebo-controlled, parallel-arm trials in adults with mild to severe OSA, LunAIRo and SynAIRgy, which together enrolled approximately 1,300 patients and represent one of the largest and most diverse cohorts ever studied in an OSA pharmacologic trial. LunAIRo was conducted in the United States and SynAIRgy was conducted in the United States and Canada. All other trials for Oxnimbi were conducted in the United States.